Soon after appointing former Allergan president Doug S. Ingram as its chief executive, Chase Pharmaceuticals has raised $12 million in a new equity round, according to a regulatory filing. The startup is developing drugs to improve the symptoms of Alzheimer’s – with drugs that improve cognition and behavioral symptoms associated with the neurodegenerative disease.
Ingram joined the Washington, D.C.-based Chase Pharmaceuticals this past December. He led Allergan until its acquisition, a year ago, by Actavis Pharmaceuticals – a merge that ultimately led to that $160 billion Pfizer coupling.
